Table 3.

Optical Coherence Tomography Central Subfield Thickness Outcomes by Baseline Central Subfield Thickness and Visual Acuity

	≥400 microns			<400 microns
Baseline Visual Acuity 20/50 or Worse (Letter Score <69)
	Aflibercept (N = 61)	Bevacizumab (N = 61)	Ranibizumab (N = 50)	Aflibercept (N = 40)	Bevacizumab (N = 39)	Ranibizumab (N = 49)
Baseline CSF (μm)
Mean ± SD	534 ± 128	558 ± 130	540 ± 106	327 ± 44	323 ± 39	320 ± 50
1 Year (μm)
Mean ± SD	244 ± 96	373 ± 175	269 ± 109	229 ± 51	258 ± 71	234 ± 68
Change from baseline (μm)
Mean ± SD	−203 ± 285	−181 ± 170	−266 ± 152	−97 ± 60	−63 ± 77	−85 ± 78
Baseline Visual Acuity 20/32–20/40 (Letter Score 78–69)
	Aflibercept (N = 32)	Bevacizumab (N = 30)	Ranibizumab (N = 43)	Aflibercept (N = 72)	Bevacizumab (N = 73)	Ranibizumab (N = 59)
Baseline CSF (μm)
Mean ± SD	499 ± 103	471 ± 75	479 ± 68	317 ± 45	318 ± 44	314 ± 45
1 Year (μm)
Mean ± SD	260 ± 73	365 ± 100	277 ± 103	233 ± 46	265 ± 50	253 ± 65
Change from baseline (μm)
Mean ± SD	−235 ± 134	−104 ± 86	−198 ± 106	−82 ± 50	−52 ± 47	−61 ± 66

SD = standard deviation; CI = confidence interval

CST values usually were translated2 to an equivalent thickness based on a Stratus time domain OCT.

^*Treatment group comparisons are means from ANCOVA models adjusted for baseline visual acuity (continuous), baseline central subfield thickness (continuous), the three-way interaction of baseline visual acuity (categorical), baseline central subfield thickness (categorical) and treatment and all two-way interactions (categorical).

Baseline central subfield thickness data missing for 2 eyes in the aflibercept group, 2 eyes in the bevacizumab group and 3 eyes in the ranibizumab.

One-year central subfield thickness data missing for 1 eye in the aflibercept group, 1 eye in the bevacizumab group and 2 eyes in the ranibizumab.

One-year visit data unavailable for 16 eyes in the aflibercept group, 12 eyes in the bevacizumab group, and 12 eyes in the ranibizumab group.